Tiziana Life Sciences (TLSA) Liabilities and Shareholders Equity (2017 - 2025)

Tiziana Life Sciences (TLSA) has reported Liabilities and Shareholders Equity for 9 consecutive years, with $11.5 million the latest figure, recorded in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 1.87% year-over-year to $11.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $50.3 million (down 2.91% YoY) and the FY2025 annual result came in at $11.5 million, up 1.87% from the prior year.
• Liabilities and Shareholders Equity declined to $11.5 million in Q4 2025 per TLSA's latest filing, from $16.6 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for TLSA reached as high as $58.6 million in Q2 2021 and fell as low as $11.0 million in Q2 2024.
• A 5-year average of $24.9 million and a median of $17.0 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity soared 349.85% — and 2023, when it slumped 53.98%.
• Year by year, Liabilities and Shareholders Equity stood at $48.8 million in 2021, then plunged by 45.77% to $26.5 million in 2022, then sank by 53.98% to $12.2 million in 2023, then declined by 7.39% to $11.3 million in 2024, then climbed by 1.87% to $11.5 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $11.5 million, $16.6 million, and $11.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.